Novadaq Technologies Inc.
TSX : NDQ

Novadaq Technologies Inc.

April 12, 2005 09:00 ET

Novadaq Reports Positive Results in CABG Study

Data Presented at the American Association for Thoracic Surgery

TORONTO, ONTARIO--(Marketwire - April 12, 2005) - Novadaq™ Technologies today announced that Drs. Nimesh Desai and Stephen Fremes
reported data on a 106-patient randomized clinical trial conducted at Sunnybrook and Women's College Health Sciences Centre in Toronto,
Canada, a fully affiliated teaching hospital of the University of Toronto, using Novadaq's proprietary Spy™ Intra-operative Imaging
System. The study was designed to compare the diagnostic accuracy of two competing technologies that verify the quality of bypass grafts
constructed during Coronary Artery Bypass Surgery. The presentation, A Randomized Comparison of Intraoperative Angiography and
Transit-Time Flow Measurement to Detect Technical Errors in Coronary Bypass Grafts, was presented today at the 85th Annual Meeting of the
American Association for Thoracic Surgery in San Francisco, California.

Currently there is no standardized practical approach to intra-operatively verify the quality of coronary bypass grafts and up to 12% of
bypass grafts are not working immediately after heart bypass surgery. The cause of early graft failures is often technical errors that
could be corrected if they were seen at the time of the operation. Intra-operative graft angiography with the SPY™ System involves
intravascular administration of fluorescent indocyanine green dye (ICG) and visualization of the graft with dispersed laser light.
Transit Time Ultrasound Flow Measurement (TTF), the most commonly used form of intra-operative graft quality verification, uses an
intra-operative ultrasound probe to measure flow value and pattern. In this randomized study, 139 bypass grafts were examined with the
SPY™ System and TTF. The primary endpoint was to compare the ability of each system to correctly identify grafts with problems using
standard x-ray angiography as the 'gold standard'. The SPY™ System demonstrated superior diagnostic accuracy and was able to correctly
identify 58% more bypass grafts with technical problems than TTF.

Since graft patency is the predominant predictor of long-term survival after coronary surgery, the lack of a reliable and well-validated
method to assess graft patency during surgery means this is a significant opportunity to improve quality assurance, said Dr. Nimesh
Desai. This data clearly demonstrates that the SPY™ System provides superior diagnostic accuracy in detecting clinically significant
graft errors as compared to the commonly used transit-time flow measurement.

About the SPY™ Intra-operative Imaging System

Novadaq's SPY™ Intra-operative Imaging System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use
during CABG surgery. SPY™ is the first intra-operative fluorescent imaging system that enables cardiac surgeons to confirm the
location of the coronary arteries and assess bypass graft functionality during coronary artery bypass procedures. The SPY™ System
enables the surgeon to view, record, replay, print and archive high quality real-time images of the coronary arteries and bypass grafts.

About Novadaq Technologies

Novadaq is focused on developing and marketing diagnostic and therapeutic medical devices for vascular imaging. Novadaq's SPY™ system
fulfils the unmet need of validating a successful revascularization during CABG surgery. Novadaq's ophthalmic product is aimed at the
diagnosis and treatment of wet Age Related Macular Degeneration (AMD) by using the same core imaging technology that is used in the SPY™
Intra-operative Imaging System.

For more information, please visit the company's website at www.novadaq.com.

Contact Information